Generic platelet drug put to the test: will it match the original?
NCT ID NCT06768619
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study checked whether a generic eltrombopag olamine tablet works the same as the brand-name version in 36 healthy Chinese adults after a meal. Participants took a single dose of each formulation in random order, and researchers measured how the drug moved through their bodies. The goal was to confirm bioequivalence, which could lead to a more affordable option for treating low platelet counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eltrombopag olamine (a drug that boosts platelet production)
- What this could lead to
- If successful, this could confirm that the generic tablet is equivalent to the brand-name drug, offering a more affordable treatment option for people with low platelet counts.
- What could go wrong
- This is a small, early-stage bioequivalence study in healthy people, not patients. It does not test whether the drug actually improves health outcomes, and results may not predict real-world effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changchun University of Traditional Chinese Medicine Affiliated Hospital
Changchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Cord blood cells aim to speed platelet recovery in transplant patients
- Platelet transfusions may influence blood vessel health in critically ill patients
- New drug strategy may reduce blood transfusions after organ transplants
- Blood test could predict bleeding risk in cancer patients
- New study tests rapid blood test to prevent bleeding emergencies in pregnancy